VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q59698173 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241020233029.0
008 241020nneanz||abbn n and d
035 ‎‡a (WKP)Q59698173‏
024 ‎‡a 0000-0003-2003-3769‏ ‎‡2 orcid‏
024 ‎‡a 35214887900‏ ‎‡2 scopus‏
035 ‎‡a (OCoLC)Q59698173‏
100 0 ‎‡a Maria A Garcia‏ ‎‡c researcher ORCID ID = 0000-0003-2003-3769‏ ‎‡9 en‏
375 ‎‡a 2‏ ‎‡2 iso5218‏
400 0 ‎‡a Maria A Garcia‏ ‎‡c onderzoeker‏ ‎‡9 nl‏
670 ‎‡a Author's 1-(Benzenesulfonyl)-1,5-dihydro-4,1-benzoxazepine as a new scaffold for the design of antitumor compounds‏
670 ‎‡a Author's 5-Fluorouracil derivatives: a patent review (2012 - 2014).‏
670 ‎‡a Author's A formulation of pancreatic pro-enzymes provides potent anti-tumour efficacy: a pilot study focused on pancreatic and ovarian cancer.‏
670 ‎‡a Author's Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling‏
670 ‎‡a Author's Activation of NF-kB pathway by virus infection requires Rb expression‏
670 ‎‡a Author's Activation of the double-stranded RNA-dependent protein kinase PKR by small ubiquitin-like modifier‏
670 ‎‡a Author's Activation of the double-stranded RNA-dependent protein kinase PKR by small ubiquitin-like modifier (SUMO).‏
670 ‎‡a Author's Anti-apoptotic and oncogenic properties of the dsRNA-binding protein of vaccinia virus, E3L.‏
670 ‎‡a Author's Bozepinib, a novel small antitumor agent, induces PKR-mediated apoptosis and synergizes with IFNα triggering apoptosis, autophagy and senescence‏
670 ‎‡a Author's Cardiomyogenic differentiation potential of human endothelial progenitor cells isolated from patients with myocardial infarction‏
670 ‎‡a Author's Caspase 9 activation by the dsRNA-dependent protein kinase, PKR: molecular mechanism and relevance.‏
670 ‎‡a Author's Clinical and therapeutic potential of protein kinase PKR in cancer and metabolism‏
670 ‎‡a Author's Clinical failure of nanoparticles in cancer: mimicking nature's solutions‏
670 ‎‡a Author's Control of virus infection by tumour suppressors.‏
670 ‎‡a Author's Enantiospecific synthesis of heterocycles linked to purines: different apoptosis modulation of enantiomers in breast cancer cells‏
670 ‎‡a Author's How Can Nanotechnology Help to Repair the Body? Advances in Cardiac, Skin, Bone, Cartilage and Nerve Tissue Regeneration‏
670 ‎‡a Author's Human gene profiling in response to the active protein kinase, interferon-induced serine/threonine protein kinase (PKR), in infected cells. Involvement of the transcription factor ATF-3 IN PKR-induced apoptosis.‏
670 ‎‡a Author's In vitro treatment of carcinoma cell lines with pancreatic (pro)enzymes suppresses the EMT programme and promotes cell differentiation‏
670 ‎‡a Author's Involvement of PKR and RNase L in translational control and induction of apoptosis after Hepatitis C polyprotein expression from a vaccinia virus recombinant‏
670 ‎‡a Author's Low adherent cancer cell subpopulations are enriched in tumorigenic and metastatic epithelial-to-mesenchymal transition-induced cancer stem-like cells.‏
670 ‎‡a Author's Mesenchymal stem cell's secretome promotes selective enrichment of cancer stem-like cells with specific cytogenetic profile‏
670 ‎‡a Author's New (RS)-benzoxazepin-purines with antitumour activity: The chiral switch from (RS)-2,6-dichloro-9-[1-(p-nitrobenzenesulfonyl)-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]-9H-purine.‏
670 ‎‡a Author's Pancreatic (pro)enzymes treatment suppresses BXPC-3 pancreatic Cancer Stem Cell subpopulation and impairs tumour engrafting‏
670 ‎‡a Author's Polymers, scaffolds and bioactive molecules with therapeutic properties in osteochondral pathologies: what's new?‏
670 ‎‡a Author's Resistance to viral infection of super p53 mice.‏
670 ‎‡a Author's SIRT1 stabilizes PML promoting its sumoylation‏
670 ‎‡a Author's Synthesis and anticancer activity of (RS)-9-(2,3-dihydro-1,4-benzoxaheteroin-2-ylmethyl)-9H-purines.‏
670 ‎‡a Author's Synthesis and anticancer activity of the (R,S)-benzofused 1,5-oxathiepine moiety tethered to purines through alkylidenoxy linkers.‏
670 ‎‡a Author's The catalytic activity of dsRNA-dependent protein kinase, PKR, is required for NF-kappaB activation.‏
670 ‎‡a Author's The chemotherapeutic drug 5-fluorouracil promotes PKR-mediated apoptosis in a p53-independent manner in colon and breast cancer cells‏
670 ‎‡a Author's The dsRNA protein kinase PKR: virus and cell control‏
670 ‎‡a Author's The impact of PKR activation: from neurodegeneration to cancer.‏
670 ‎‡a Author's Uncovering Tumour Heterogeneity through PKR and nc886 Analysis in Metastatic Colon Cancer Patients Treated with 5-FU-Based Chemotherapy‏
670 ‎‡a Author's Validation of suitable normalizers for miR expression patterns analysis covering tumour heterogeneity.‏
909 ‎‡a (orcid) 0000000320033769‏ ‎‡9 1‏
909 ‎‡a (scopus) 35214887900‏ ‎‡9 1‏
919 ‎‡a bozepinibanovelsmallantitumoragentinducespkrmediatedapoptosisandsynergizeswithifnαtriggeringapoptosisautophagyandsenescence‏ ‎‡A Bozepinib, a novel small antitumor agent, induces PKR-mediated apoptosis and synergizes with IFNα triggering apoptosis, autophagy and senescence‏ ‎‡9 1‏
919 ‎‡a antiapoptoticandoncogenicpropertiesofthedsrnabindingproteinofvacciniaviruse3l‏ ‎‡A Anti-apoptotic and oncogenic properties of the dsRNA-binding protein of vaccinia virus, E3L.‏ ‎‡9 1‏
919 ‎‡a 1benzenesulfonyl15dihydro41benzoxazepineasanewscaffoldforthedesignofantitumorcompounds‏ ‎‡A 1-(Benzenesulfonyl)-1,5-dihydro-4,1-benzoxazepine as a new scaffold for the design of antitumor compounds‏ ‎‡9 1‏
919 ‎‡a 5fluorouracilderivativesapatentreview2012‏ ‎‡A 5-Fluorouracil derivatives: a patent review (2012 - 2014).‏ ‎‡9 1‏
919 ‎‡a activationofthedoublestrandedrnadependentproteinkinasepkrbysmallubiquitinlikemodifiersumo‏ ‎‡A Activation of the double-stranded RNA-dependent protein kinase PKR by small ubiquitin-like modifier (SUMO).‏ ‎‡9 1‏
919 ‎‡a formulationofpancreaticproenzymesprovidespotentantitumourefficacyapilotstudyfocusedonpancreaticandovariancancer‏ ‎‡A A formulation of pancreatic pro-enzymes provides potent anti-tumour efficacy: a pilot study focused on pancreatic and ovarian cancer.‏ ‎‡9 1‏
919 ‎‡a activatingtranscriptionfactor4modulatestgfβinducedaggressivenessintriplenegativebreastcancerviasmad234andmtorc2signaling‏ ‎‡A Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling‏ ‎‡9 1‏
919 ‎‡a activationofnfkbpathwaybyvirusinfectionrequiresrbexpression‏ ‎‡A Activation of NF-kB pathway by virus infection requires Rb expression‏ ‎‡9 1‏
919 ‎‡a activationofthedoublestrandedrnadependentproteinkinasepkrbysmallubiquitinlikemodifier‏ ‎‡A Activation of the double-stranded RNA-dependent protein kinase PKR by small ubiquitin-like modifier‏ ‎‡9 1‏
919 ‎‡a validationofsuitablenormalizersformirexpressionpatternsanalysiscoveringtumourheterogeneity‏ ‎‡A Validation of suitable normalizers for miR expression patterns analysis covering tumour heterogeneity.‏ ‎‡9 1‏
919 ‎‡a uncoveringtumourheterogeneitythroughpkrandnc886analysisinmetastaticcoloncancerpatientstreatedwith5fubasedchemotherapy‏ ‎‡A Uncovering Tumour Heterogeneity through PKR and nc886 Analysis in Metastatic Colon Cancer Patients Treated with 5-FU-Based Chemotherapy‏ ‎‡9 1‏
919 ‎‡a impactofpkractivationfromneurodegenerationtocancer‏ ‎‡A The impact of PKR activation: from neurodegeneration to cancer.‏ ‎‡9 1‏
919 ‎‡a dsrnaproteinkinasepkrvirusandcellcontrol‏ ‎‡A The dsRNA protein kinase PKR: virus and cell control‏ ‎‡9 1‏
919 ‎‡a chemotherapeuticdrug5fluorouracilpromotespkrmediatedapoptosisinap53independentmannerincolonandbreastcancercells‏ ‎‡A The chemotherapeutic drug 5-fluorouracil promotes PKR-mediated apoptosis in a p53-independent manner in colon and breast cancer cells‏ ‎‡9 1‏
919 ‎‡a catalyticactivityofdsrnadependentproteinkinasepkrisrequiredfornfkappabactivation‏ ‎‡A The catalytic activity of dsRNA-dependent protein kinase, PKR, is required for NF-kappaB activation.‏ ‎‡9 1‏
919 ‎‡a synthesisandanticanceractivityofthersbenzofused15oxathiepinemoietytetheredtopurinesthroughalkylidenoxylinkers‏ ‎‡A Synthesis and anticancer activity of the (R,S)-benzofused 1,5-oxathiepine moiety tethered to purines through alkylidenoxy linkers.‏ ‎‡9 1‏
919 ‎‡a synthesisandanticanceractivityofrs923dihydro14benzoxaheteroin2ylmethyl9hpurines‏ ‎‡A Synthesis and anticancer activity of (RS)-9-(2,3-dihydro-1,4-benzoxaheteroin-2-ylmethyl)-9H-purines.‏ ‎‡9 1‏
919 ‎‡a sirt1stabilizespmlpromotingitssumoylation‏ ‎‡A SIRT1 stabilizes PML promoting its sumoylation‏ ‎‡9 1‏
919 ‎‡a resistancetoviralinfectionofsuperp53mice‏ ‎‡A Resistance to viral infection of super p53 mice.‏ ‎‡9 1‏
919 ‎‡a polymersscaffoldsandbioactivemoleculeswiththerapeuticpropertiesinosteochondralpathologieswhatsnew‏ ‎‡A Polymers, scaffolds and bioactive molecules with therapeutic properties in osteochondral pathologies: what's new?‏ ‎‡9 1‏
919 ‎‡a pancreaticproenzymestreatmentsuppressesbxpc3pancreaticcancerstemcellsubpopulationandimpairstumourengrafting‏ ‎‡A Pancreatic (pro)enzymes treatment suppresses BXPC-3 pancreatic Cancer Stem Cell subpopulation and impairs tumour engrafting‏ ‎‡9 1‏
919 ‎‡a newrsbenzoxazepinpurineswithantitumouractivitythechiralswitchfromrs26dichloro99hpurine‏ ‎‡A New (RS)-benzoxazepin-purines with antitumour activity: The chiral switch from (RS)-2,6-dichloro-9-[1-(p-nitrobenzenesulfonyl)-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]-9H-purine.‏ ‎‡9 1‏
919 ‎‡a mesenchymalstemcellssecretomepromotesselectiveenrichmentofcancerstemlikecellswithspecificcytogeneticprofile‏ ‎‡A Mesenchymal stem cell's secretome promotes selective enrichment of cancer stem-like cells with specific cytogenetic profile‏ ‎‡9 1‏
919 ‎‡a lowadherentcancercellsubpopulationsareenrichedintumorigenicandmetastaticepithelialtomesenchymaltransitioninducedcancerstemlikecells‏ ‎‡A Low adherent cancer cell subpopulations are enriched in tumorigenic and metastatic epithelial-to-mesenchymal transition-induced cancer stem-like cells.‏ ‎‡9 1‏
919 ‎‡a involvementofpkrandrnase50intranslationalcontrolandinductionofapoptosisafterhepatitis100polyproteinexpressionfromavacciniavirusrecombinant‏ ‎‡A Involvement of PKR and RNase L in translational control and induction of apoptosis after Hepatitis C polyprotein expression from a vaccinia virus recombinant‏ ‎‡9 1‏
919 ‎‡a invitrotreatmentofcarcinomacelllineswithpancreaticproenzymessuppressestheemtprogrammeandpromotescelldifferentiation‏ ‎‡A In vitro treatment of carcinoma cell lines with pancreatic (pro)enzymes suppresses the EMT programme and promotes cell differentiation‏ ‎‡9 1‏
919 ‎‡a humangeneprofilinginresponsetotheactiveproteinkinaseinterferoninducedserinethreonineproteinkinasepkrininfectedcellsinvolvementofthetranscriptionfactoratf3inpkrinducedapoptosis‏ ‎‡A Human gene profiling in response to the active protein kinase, interferon-induced serine/threonine protein kinase (PKR), in infected cells. Involvement of the transcription factor ATF-3 IN PKR-induced apoptosis.‏ ‎‡9 1‏
919 ‎‡a howcannanotechnologyhelptorepairthebodyadvancesincardiacskinbonecartilageandnervetissueregeneration‏ ‎‡A How Can Nanotechnology Help to Repair the Body? Advances in Cardiac, Skin, Bone, Cartilage and Nerve Tissue Regeneration‏ ‎‡9 1‏
919 ‎‡a enantiospecificsynthesisofheterocycleslinkedtopurinesdifferentapoptosismodulationofenantiomersinbreastcancercells‏ ‎‡A Enantiospecific synthesis of heterocycles linked to purines: different apoptosis modulation of enantiomers in breast cancer cells‏ ‎‡9 1‏
919 ‎‡a controlofvirusinfectionbytumoursuppressors‏ ‎‡A Control of virus infection by tumour suppressors.‏ ‎‡9 1‏
919 ‎‡a clinicalfailureofnanoparticlesincancermimickingnaturessolutions‏ ‎‡A Clinical failure of nanoparticles in cancer: mimicking nature's solutions‏ ‎‡9 1‏
919 ‎‡a clinicalandtherapeuticpotentialofproteinkinasepkrincancerandmetabolism‏ ‎‡A Clinical and therapeutic potential of protein kinase PKR in cancer and metabolism‏ ‎‡9 1‏
919 ‎‡a caspase9activationbythedsrnadependentproteinkinasepkrmolecularmechanismandrelevance‏ ‎‡A Caspase 9 activation by the dsRNA-dependent protein kinase, PKR: molecular mechanism and relevance.‏ ‎‡9 1‏
919 ‎‡a cardiomyogenicdifferentiationpotentialofhumanendothelialprogenitorcellsisolatedfrompatientswithmyocardialinfarction‏ ‎‡A Cardiomyogenic differentiation potential of human endothelial progenitor cells isolated from patients with myocardial infarction‏ ‎‡9 1‏
943 ‎‡a 201x‏ ‎‡A 2014‏ ‎‡9 1‏
946 ‎‡a a‏ ‎‡9 1‏
996 ‎‡2 B2Q|0000862156‏
996 ‎‡2 DNB|171362799‏
996 ‎‡2 BNE|XX4687723‏
996 ‎‡2 LC|n 2022025940‏
996 ‎‡2 BNC|981058516153106706‏
996 ‎‡2 BNC|981061020617306706‏
996 ‎‡2 ISNI|0000000506744382‏
996 ‎‡2 ISNI|0000000060452747‏
996 ‎‡2 BNE|XX1101567‏
996 ‎‡2 LC|n 2006184411‏
996 ‎‡2 SUDOC|250800845‏
996 ‎‡2 NII|DA09109031‏
996 ‎‡2 BNE|XX1554159‏
996 ‎‡2 BIBSYS|3033514‏
996 ‎‡2 PTBNP|1546828‏
996 ‎‡2 BNE|XX1026516‏
996 ‎‡2 RERO|A013229577‏
996 ‎‡2 LC|no2019104409‏
996 ‎‡2 BNE|XX5490051‏
996 ‎‡2 LC|n 94050983‏
996 ‎‡2 PTBNP|79133‏
996 ‎‡2 BNE|XX1168168‏
996 ‎‡2 SUDOC|138937478‏
996 ‎‡2 SUDOC|149310900‏
996 ‎‡2 DNB|1080932313‏
996 ‎‡2 ISNI|0000000036264295‏
996 ‎‡2 SUDOC|117622958‏
996 ‎‡2 ISNI|0000000380696652‏
996 ‎‡2 BNE|XX821592‏
996 ‎‡2 LC|n 92075402‏
996 ‎‡2 SUDOC|170045005‏
996 ‎‡2 ISNI|0000000059376177‏
996 ‎‡2 SUDOC|083796606‏
996 ‎‡2 ISNI|0000000059317943‏
996 ‎‡2 LC|nr 95031051‏
996 ‎‡2 BNE|XX5618003‏
996 ‎‡2 DNB|1079630740‏
996 ‎‡2 ISNI|0000000040044076‏
996 ‎‡2 LC|nr 92014039‏
996 ‎‡2 SUDOC|034234098‏
996 ‎‡2 PLWABN|9810948358405606‏
996 ‎‡2 BNE|XX1279716‏
996 ‎‡2 ISNI|0000000060226168‏
996 ‎‡2 ISNI|0000000046491803‏
996 ‎‡2 LC|n 94068391‏
996 ‎‡2 LC|no2008165135‏
996 ‎‡2 LC|n 2022016138‏
996 ‎‡2 DNB|1057558745‏
996 ‎‡2 ISNI|0000000354435299‏
996 ‎‡2 PTBNP|254657‏
996 ‎‡2 DNB|1074665511‏
996 ‎‡2 BNC|981058516075806706‏
996 ‎‡2 ISNI|0000000118813112‏
996 ‎‡2 BNE|XX5417358‏
996 ‎‡2 BNE|XX880910‏
996 ‎‡2 J9U|987007592497505171‏
996 ‎‡2 ISNI|0000000019471778‏
996 ‎‡2 SUDOC|25269029X‏
996 ‎‡2 BNE|XX1734804‏
996 ‎‡2 NTA|240046749‏
996 ‎‡2 BNE|XX1343583‏
996 ‎‡2 BNE|XX939772‏
996 ‎‡2 DNB|188481672‏
996 ‎‡2 BNE|XX834598‏
996 ‎‡2 ISNI|000000007023273X‏
996 ‎‡2 BNE|XX1597714‏
996 ‎‡2 SZ|1057407208‏
996 ‎‡2 ISNI|0000000059509726‏
996 ‎‡2 BNF|17815981‏
996 ‎‡2 ISNI|0000000356260744‏
996 ‎‡2 LC|ns2016003002‏
996 ‎‡2 BNF|16144476‏
996 ‎‡2 SUDOC|270131280‏
996 ‎‡2 LC|no2002083613‏
996 ‎‡2 ISNI|0000000450513322‏
996 ‎‡2 ISNI|0000000059987760‏
996 ‎‡2 NUKAT|n 2003060315‏
996 ‎‡2 BNE|XX4610668‏
996 ‎‡2 BNC|981058525096506706‏
996 ‎‡2 SUDOC|05710400X‏
996 ‎‡2 ISNI|000000004656972X‏
996 ‎‡2 J9U|987007276279405171‏
996 ‎‡2 LC|no2023035245‏
996 ‎‡2 BNF|12460619‏
996 ‎‡2 BNE|XX5674770‏
996 ‎‡2 BNF|13476625‏
996 ‎‡2 DNB|141123842‏
996 ‎‡2 BNC|981058515988806706‏
996 ‎‡2 BNE|XX1393761‏
996 ‎‡2 BNC|981058610462506706‏
996 ‎‡2 LC|no2013119984‏
996 ‎‡2 DNB|1304905349‏
996 ‎‡2 LC|no2007158873‏
996 ‎‡2 LC|no2019031205‏
996 ‎‡2 ISNI|0000000060907473‏
996 ‎‡2 DNB|1343135141‏
996 ‎‡2 LC|no2022106463‏
996 ‎‡2 BNE|XX6467249‏
996 ‎‡2 BNC|981058616368406706‏
996 ‎‡2 LC|nr 94006549‏
996 ‎‡2 ISNI|0000000079764476‏
996 ‎‡2 BNC|981058511183006706‏
996 ‎‡2 LC|n 82038287‏
996 ‎‡2 DNB|124840922‏
996 ‎‡2 ISNI|0000000049966077‏
996 ‎‡2 PTBNP|1535939‏
996 ‎‡2 LC|no2010076443‏
996 ‎‡2 LC|n 84155355‏
996 ‎‡2 ISNI|0000000064398610‏
996 ‎‡2 W2Z|9015740‏
996 ‎‡2 NII|DA16271197‏
996 ‎‡2 BNC|981058518088506706‏
996 ‎‡2 LC|n 2005055992‏
996 ‎‡2 LC|n 2018185962‏
996 ‎‡2 LC|n 78028587‏
996 ‎‡2 DNB|1057070750‏
996 ‎‡2 LC|no2008077996‏
996 ‎‡2 LC|ns2018002319‏
996 ‎‡2 LC|n 2017035655‏
996 ‎‡2 ISNI|0000000060295841‏
996 ‎‡2 LC|nr 94017717‏
996 ‎‡2 LC|n 2008005183‏
996 ‎‡2 CAOONL|ncf10326153‏
996 ‎‡2 BNE|XX1095833‏
996 ‎‡2 LC|ns2012004391‏
996 ‎‡2 BNE|XX961082‏
996 ‎‡2 DNB|1056444878‏
996 ‎‡2 RERO|A006362372‏
996 ‎‡2 ISNI|0000000081614143‏
996 ‎‡2 DNB|1115278290‏
996 ‎‡2 LC|no2008058785‏
996 ‎‡2 ISNI|0000000066367797‏
996 ‎‡2 SUDOC|275961796‏
996 ‎‡2 BNE|XX1282349‏
996 ‎‡2 SUDOC|168355167‏
996 ‎‡2 ISNI|0000000071414762‏
996 ‎‡2 CAOONL|ncf11376711‏
996 ‎‡2 NYNYRILM|384211‏
996 ‎‡2 BNF|11885584‏
996 ‎‡2 LC|no 97028643‏
996 ‎‡2 BNE|XX950723‏
996 ‎‡2 BNE|XX950722‏
996 ‎‡2 ISNI|0000000066363833‏
996 ‎‡2 ISNI|0000000067535617‏
996 ‎‡2 SUDOC|085799602‏
996 ‎‡2 BNE|XX5898596‏
996 ‎‡2 NTA|432998977‏
996 ‎‡2 BNF|14526339‏
996 ‎‡2 LC|no2007057731‏
996 ‎‡2 BNE|XX867525‏
996 ‎‡2 BNE|XX885537‏
996 ‎‡2 PTBNP|263602‏
996 ‎‡2 ISNI|0000000048426204‏
996 ‎‡2 DNB|1035572702‏
996 ‎‡2 BNC|981058516314006706‏
996 ‎‡2 NUKAT|n 2009146582‏
996 ‎‡2 SUDOC|170551830‏
996 ‎‡2 BNE|XX1741747‏
996 ‎‡2 SUDOC|271004355‏
996 ‎‡2 ISNI|0000000079704756‏
996 ‎‡2 LC|no2009159394‏
996 ‎‡2 ISNI|0000000115571453‏
996 ‎‡2 BNE|XX1224382‏
996 ‎‡2 LC|no2021073341‏
996 ‎‡2 BNC|981058510154506706‏
996 ‎‡2 SUDOC|14015762X‏
996 ‎‡2 B2Q|0000772712‏
996 ‎‡2 LC|no2009096201‏
996 ‎‡2 NUKAT|n 2016054369‏
996 ‎‡2 BLBNB|000215078‏
996 ‎‡2 LC|ns2024002444‏
996 ‎‡2 DNB|1038158761‏
996 ‎‡2 BNC|981058520815306706‏
996 ‎‡2 LC|n 2017251616‏
996 ‎‡2 LC|n 80098304‏
996 ‎‡2 BNE|XX854760‏
996 ‎‡2 SUDOC|195145941‏
996 ‎‡2 ISNI|0000000060503911‏
996 ‎‡2 BNF|15569921‏
996 ‎‡2 DNB|1057280798‏
996 ‎‡2 DNB|124546597X‏
996 ‎‡2 LC|n 94116053‏
996 ‎‡2 NTA|27974952X‏
996 ‎‡2 SELIBR|222039‏
996 ‎‡2 RERO|A027591050‏
996 ‎‡2 SIMACOB|35608163‏
996 ‎‡2 DNB|1048248135‏
996 ‎‡2 PTBNP|1309842‏
996 ‎‡2 J9U|987007440820105171‏
996 ‎‡2 DNB|1074373324‏
996 ‎‡2 B2Q|0001195271‏
996 ‎‡2 LC|no2021034371‏
996 ‎‡2 BNE|XX993034‏
996 ‎‡2 PTBNP|1488463‏
996 ‎‡2 BNE|XX957843‏
996 ‎‡2 DNB|105738481X‏
996 ‎‡2 BNC|981058529856206706‏
996 ‎‡2 ISNI|0000000044763588‏
996 ‎‡2 LC|n 85306757‏
996 ‎‡2 LC|ns2012000155‏
996 ‎‡2 ISNI|0000000021672720‏
996 ‎‡2 DNB|138316597‏
996 ‎‡2 NUKAT|n 2020029416‏
996 ‎‡2 ISNI|0000000357034052‏
996 ‎‡2 LC|n 2021048953‏
996 ‎‡2 LC|no2001031475‏
996 ‎‡2 LC|n 2001088748‏
996 ‎‡2 BNE|XX1167773‏
996 ‎‡2 ISNI|0000000083731941‏
996 ‎‡2 SUDOC|243167296‏
996 ‎‡2 ISNI|0000000111037544‏
996 ‎‡2 BNF|12239675‏
996 ‎‡2 ISNI|0000000454881739‏
996 ‎‡2 BLBNB|000268815‏
996 ‎‡2 ISNI|0000000059530007‏
996 ‎‡2 BNC|981058516784606706‏
996 ‎‡2 LC|nr2007002222‏
996 ‎‡2 BNE|XX872274‏
996 ‎‡2 LC|n 2008217204‏
996 ‎‡2 BNC|981058604779406706‏
996 ‎‡2 BNE|XX899830‏
996 ‎‡2 BNE|XX1272702‏
996 ‎‡2 ISNI|0000000476678897‏
996 ‎‡2 SUDOC|083843051‏
996 ‎‡2 BNCHL|10000000000000000044141‏
996 ‎‡2 NUKAT|n 2022034312‏
996 ‎‡2 ISNI|0000000079149924‏
996 ‎‡2 BNE|XX5050356‏
996 ‎‡2 LC|no2023094361‏
996 ‎‡2 SUDOC|033755256‏
996 ‎‡2 ISNI|0000000059339368‏
996 ‎‡2 BNE|XX1470354‏
996 ‎‡2 ISNI|0000000116585582‏
996 ‎‡2 SUDOC|144196395‏
996 ‎‡2 BNE|XX6104650‏
996 ‎‡2 BNE|XX1037356‏
996 ‎‡2 BNE|XX1053806‏
996 ‎‡2 BNE|XX1082175‏
996 ‎‡2 LC|n 83205137‏
996 ‎‡2 CAOONL|ncf10897137‏
996 ‎‡2 DNB|1016243251‏
996 ‎‡2 BNE|XX5409228‏
996 ‎‡2 BIBSYS|90705046‏
996 ‎‡2 BNE|XX5589470‏
996 ‎‡2 LC|no2020067701‏
996 ‎‡2 BNF|15561982‏
996 ‎‡2 LC|no2010196463‏
996 ‎‡2 BNE|XX940567‏
996 ‎‡2 BNE|XX1099866‏
996 ‎‡2 SUDOC|134510526‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏